NDAINTRAVENOUS, ORALPOWDER
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VANCOMYCIN HYDROCHLORIDE (vancomycin hydrochloride) by Inpharmus is clinical pharmacology vancomycin is poorly absorbed after oral administration. First approved in 2023.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Vancomycin hydrochloride is a glycopeptide antibiotic administered intravenously or orally that inhibits bacterial cell-wall biosynthesis, making it a critical agent against gram-positive infections including resistant Staphylococcus aureus and enterococci. It alters bacterial cell-membrane permeability and RNA synthesis, with no cross-resistance to other antibiotic classes. Patients with serious gram-positive infections, particularly those resistant to beta-lactams, depend on vancomycin as a cornerstone therapy.
Peak
Vancomycin is in peak lifecycle stage with moderate competitive pressure (30/100), indicating a stable, mature portfolio requiring defensive positioning and operational excellence.
Mechanism of Action
CLINICAL PHARMACOLOGY Vancomycin is poorly absorbed after oral administration. In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion…
Worked on VANCOMYCIN HYDROCHLORIDE at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.